RNN Rexahn Pharmaceuticals, Inc. Co

0.43
+0  (2%)
Previous Close 0.42
Open 0.43
Price To book 5.83
Market Cap 101.39M
Shares 237,443,000
Volume 2,719,491
Short Ratio 1.55
Av. Daily Volume 6,485,830

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2Q 2018.
RX-3117 in combination with Abraxane
First-line pancreatic cancer
Phase 2a initial data due mid-2017.
RX-3117
Advanced bladder cancer
Phase 2a initiation of dosing announced February 23, 2017, initial data due 2H 2017.
Supinoxin
Triple negative breast cancer
Updated Phase 2a data presented at ASCO GI January 20, 2017. Final data due 2H 2017.
RX-3117
Relapsed and refractory pancreatic cancer
Phase 2a second stage enrollment commenced February 2016. Data due mid-2017.
Archexin
Renal cell carcinoma (RCC) - cancer